SBWire

ABC Pharmacy of Beverly Hills, a preeminent pharmacy Beverly Hills recently announced it is now offering its top-rated service to Los Angeles and all surrounding communities. The pharmacy Beverly Hills quickly developed a reputation as being a leading provider of pharmaceutical elements in Los Angeles and all surrounding communities.

Q BioMed Inc., a biotechnology acceleration company is pleased to congratulate Mannin Research on its selection to the C2MP program and the exceptional mentors and advisors now included in the long list of industry experts available to assist in advancing these important technologies.

Myocardial infarction, commonly known as heart attack, is the irreparable death of the heart tissue. It occurs when blood stops flowing to a part of the myocardium (heart muscle), depriving it of oxygen and nutrients. If the coronary artery that supplies blood to the heart muscle is blocked by the formation of plaque (a substance made of fat, cholesterol, and cellular waste), the heart is starved of oxygen, a condition called cardiac ischemia, causing tissue damage. Cardiac ischemia may lead to episodes of angina or chest pain. The slow build-up of plaque on the walls of the heart narrows the blood vessels and finally blocks them. Rapid flow of lipids through the vessels may also create a tear on the walls of the vessels causing aggregation of platelets and the formation of a clot. The clot formation causes obstruction of blood supply through the vessels, leading to necrosis or the death of tissues in the heart muscle.

Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company"), a bio pharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers provided investors with an update on its business progress following the filing of its 2015 10-K.

Actinium Pharmaceuticals, Inc., a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers announced today that it has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) pertaining to Iomab-B, the Company's Iodine-131 labeled anti-CD45 antibody. This provisional patent application represents the second provisional patent application filing related to Iomab-B following the Company's June 24, 2015 filing for infusion administration of Iomab-B. A provisional patent application is a legal document that establishes an early priority date for the benefit of claiming "first to file" status against other companies or individuals that may want to file a subsequent patent with similar claims.

ABC Compounding Pharmacy, the much touted Long Beach compounding pharmacy, has announced that it has begun offering services to the Long Beach Community at large. The pharmacy has decided to offer this service after much clamoring by the public for a premier Long Beach compounding pharmacy.

CEL-SCI Corporation ("CEL SCI" or the "Company") today announced that during the month of February it has enrolled 27 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) in patients with advanced primary head and neck cancer. Total patient enrollment for the trial is now 724 as of February 29, 2016 in the world's largest Phase 3 study in head and neck cancer.

GBI Research's latest report, "Evolving Market Access Strategies - Pricing and Reimbursement Landscape in Major Developed Pharmaceutical Markets" assesses developments within the key elements of market access such as Health Economics and Outcome Research (HEOR), Health Technology Assessment (HTA) as well as pricing and reimbursements strategies for pharmaceutical products. This new report also discusses the need to integrate market access strategies earlier into the drug development process, in order to save time and costs related to conducting additional studies to prove the added benefits of a product. Additionally, our new study analyses the role of HTAs in market access and alternatives that could be used in cases where there is limited evidence. Detailed analysis of pricing and reimbursement policies in North America, five key European countries and Japan are also included in this report along with a myriad of relevant case studies. In order to gain optimum market access, companies have to analyze the economic benefit of the treatment, the level of competition and the required reimbursement support.

At a conference last week in Bangkok, Thailand, Don Margolis, founder and chairman of the Repair Stem Cells Institute, issued a statement outlining how the medical establishment, (sometimes known as "Big Pharma" or simply "Pharma") deliberately obscures results of clinical trials on the use of stem cells to treat heart disease. In his statement, Margolis echoed the sentiments of Dr. Chauncey Crandall, M.D., head of preventative medicine and cardiology services at the Palm Beach Cardiovascular Clinic, who in 2013 stated the reason he would not prescribe Merck's new cholesterol treatment drug Liptruzet. Dr. Crandall had stated: "This is just another smokescreen for the drug companies to make money."

GlobalData's clinical trial report, "Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Global Clinical Trials Review, H2, 2015" provides an overview of Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) clinical trials scenario. This report provides top line data relating to the clinical trials on Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

GlobalData's clinical trial report, "Chronic Cerebrospinal Venous Insufficiency (CCSVI) Global Clinical Trials Review, H2, 2015" provides an overview of Chronic Cerebrospinal Venous Insufficiency (CCSVI) clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Cerebrospinal Venous Insufficiency (CCSVI). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

According to the Centers for Disease Control and Prevention (CDC), a vaccine is a product that stimulates a person's immune system to produce immunity to a specific disease, protecting the person from that disease. Vaccines are usually administered through needle injections, but can also be administered by mouth or sprayed into the nose.

When business establishments ranging from startups to fortune 500 companies feel the need of regulatory consultation, they more often end up with I 3 Consulting, an India based regulatory specialist with global footing. With a team of professionals falling from diverse backgrounds including medical device, pharmaceuticals, cosmetics, food and nutraceutical regulatory practice, the regulatory specialist strives to live up to their expectations at all times. Currently, I 3 Consulting is extending diligent services to enterprises based in America, Europe, Middle East and Asia-Pacific.

Immune-mediated inflammatory diseases are a very common set of chronic disorders that affect 5-7% of western populations. Although they are often disparate in terms of their symptoms and key patient demographics, they are pathophysiologically linked, being characterized by dysregulation of immune pathways and an inappropriate immune response. Generally, disease-modifying anti-rheumatic drugs, a highly genericized class of systemic small-molecule-based agents, are used in the first-line treatment of these diseases. These are supplemented in many cases by shorter-term glucocorticoid therapy, another class of highly genericized systemic agents.

Actinium Pharmaceuticals, Inc.("Actinium"), is a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium announced today the appointment of Rowena Choudrie, M.S. to the position of Senior Director, Pharmaceutical Product Development and Kevin Zikaras to the position of Senior Clinical Scientist. These hires will report to Kaushik J. Dave, Ph.D., MBA Chief Executive Officer and Felix Garzon, M.D., Ph.D., Senior Vice President, Head of Clinical Development, respectively.

The international pharmaceutical and medical supplies company B. Braun recently acquired an automated logistics center from a third party supplier and is relying on viastore to modernize the facility. The aim is to adapt the new logistics system to B. Braun's processes and safety requirements. Key to this will be a new warehouse management system (WMS) software, a new control system and improved workstation ergonomics.

GlobalData's clinical trial report, "Anovulation Global Clinical Trials Review, H2, 2015" provides an overview of Anovulation clinical trials scenario. This report provides top line data relating to the clinical trials on Anovulation. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

Leaders in Pharmaceutical Business Intelligence would like to announce the First volume of their BioMedical E-Book Series B: Genomics Orientations for Individualized Medicine, Vol. I

Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation which is now available on Amazon Kindle at www.amazon.com/dp/B018Q5MCN8.

Leaders in Pharmaceutical Business Intelligence would like to announce Volume III of their BioMedical E-Book Series E: Patient-Centered Medicine

Leaders in Pharmaceutical Business Intelligence would like to announce the Third volume of their BioMedical E-Book Series A: e-Books on Cardiovascular Diseases

Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, announced today that the U.S. Food and Drug Administration (FDA) cleared the Company's Investigational New Drug (IND) application to begin its Phase I trial of PLX-R18 cells to treat incomplete hematopoietic recovery following Hematopoietic Cell Transplantation (HCT). The clinical trial is expected to begin in the first half of 2016.

Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, today announced the publication of a scientific study of PLacental eXpanded (PLX) cells in the prominent peer-reviewed journal Clinical Science. The paper, titled "Human Placenta-Derived Stromal Cells Decrease Inflammation, Placental Injury, and Blood Pressure in Hypertensive Pregnant Mice," describes the positive findings of a recent preclinical study of PLX-PAD cells for the treatment of preeclampsia. This marks the first published study indicating the superiority of placenta-derived mesenchymal cells in a therapeutic outcome as compared to cells derived from bone marrow or fat tissue, thus having implications beyond preeclampsia. Scientists also described the potential mechanism of action by which PLX-PAD cells treated symptoms of preeclampsia. Conducted by independent scientists at the Texas A&M Health Science Center/Baylor Scott & White Health, the paper was co-authored by scientists from the Health Science Center and Pluristem Therapeutics.

Hepatitis is an inflammatory condition that occurs due to infection by hepatitis virus. It predominantly affects the liver and also causes damage to other body parts such as digestive system and brain. Apart from viral infections, hepatitis can also be caused by toxic substances, alcohol consumption, and autoimmune diseases. The viruses that cause hepatitis are of several types: A, B, C, D, E, and G. The most common type of hepatitis viruses are A, B, and C. Hepatitis viruses can cause either acute or chronic infections.

CEL-SCI Corporation("CEL SCI" or the "Company") today announced that in 2015 it enrolled 340 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) in patients with advanced primary head and neck cancer. In the month of December it enrolled 33 patients. Total patient enrollment for the trial is now 668 as of December 31, 2015 in the world's largest Phase 3 study in head and neck cancer.